Yuhan Corporation
000105.KS
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.57T
Close$
$-13158.30
119.7% downside
Current Fair Value
119.7% downsideOvervalued by 119.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.57 Trillion |
|---|---|
| Enterprise Value | $5.51 Trillion |
| Dividend Yield | $610.00 (0.82%) |
| Earnings per Share | $2599 |
| Beta | 0.42 |
| Outstanding Shares | 85,445,000 |
Return
| Return on Equity | 9.93% |
|---|---|
| Return on Assets | 7.12% |
| Return on Invested Capital | 5.42% |
Valuation & Multiples
| P/E Ratio | 25.57 |
|---|---|
| PEG | 46.96 |
| Price to Sales | 2.5 |
| Price to Book Ratio | 2.31 |
| Enterprise Value to Revenue | 2.41 |
| Enterprise Value to EBIT | 38.81 |
| Enterprise Value to Net Income | 23 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | 0.16 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 30, 2026
EPS Estimate
$771.79
Average shareholder expectationRevenue Estimate
$632.14 B
Average shareholder expectationNext Earnings Call
Expected Date
November 3, 2026
EPS Estimate
$378.41
Average shareholder expectationRevenue Estimate
$602.76 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Yuhan Corporation
2,153 employees
CEO: Wook-Je Cho Yuhan Corporation, a prominent South Korean pharmaceutical firm established in 1926 and headquartered in Seoul, specializes in the research, development, and manufacture of active pharmaceutical ingredients (APIs) and intermediates for b...